What were the earnings per share (EPS) figures, and how do they stack up against consensus estimates? | ZEAL (Aug 07, 2025) | Candlesense
ZEAL

What were the earnings per share (EPS) figures, and how do they stack up against consensus estimates?

Answer Overview

The press‑release excerpt you shared (Zealand Pharma’s Q2‑2025 earnings conference call announcement) does not contain any quantitative information about the company’s earnings per share (EPS) results, nor does it provide the analyst consensus estimates for those figures. Consequently, based on the information provided, it isn’t possible to give the exact EPS numbers or to assess how they compare to consensus expectations.

What’s Missing?

Data Point Present in the excerpt? Comments
Reported EPS (actual) No The press release only announces the upcoming conference call; it does not include the results themselves.
Consensus EPS estimate No No analyst forecast or consensus figure is mentioned.
Comparison (beat/miss) No Without both actual and estimate figures, we cannot evaluate performance relative to consensus.

What to Do Next

  1. Locate the Full Press Release

    The full press release (often labeled “Press Release – No. 11/2025” in the source) will contain the detailed financial results, including:

    • GAAP EPS (or adjusted EPS) for Q2 2025
    • The analyst consensus EPS (usually from FactSet, Bloomberg, or Refinitiv)
    • Any commentary on whether the result “beat”, “met”, or “missed” the consensus.

  2. Check the Conference Call Replay

    The conference call itself (scheduled for 14 August at 2 p.m. CET / 8 a.m. ET) typically includes a slide deck or a transcript that will detail:

    • EPS for the quarter, and sometimes year‑to‑date (YTD) EPS
    • Management’s discussion of why the EPS deviated (if at all) from expectations

  3. Review Analyst Reports

    • Look for consensus numbers on financial data platforms (e.g., Bloomberg, FactSet, Refinitiv).
    • Compare the reported EPS to the consensus to determine if the result is a beat (greater than consensus), meet (approximately equal), or miss (below consensus).

Sample Structure for the Desired Answer (once data is available)

Metric Reported Consensus Difference Interpretation
EPS (Q2 2025) $X.XX (e.g., $0.68) $Y.YY (e.g., $0.62) +$Z.ZZ (e.g., +$0.06) Beat – 9.7% above consensus
EPS (Year‑to‑date) $A.AA $B.BB +$C.CC Meet – within ±5% of consensus

Conclusion

Based on the provided news snippet, the EPS figures and consensus estimates are not disclosed, so an answer with specific numbers isn’t possible at this time. To obtain the precise EPS data and its comparison to consensus expectations, you’ll need to retrieve the full press release or the earnings release document that accompanies the August 14 conference call. Once that information is available, you can directly answer the question by listing the reported EPS, the consensus estimate, and the resulting beat/meet/miss assessment.

Other Questions About This News

Did the company announce any significant partnerships, acquisitions, or divestitures during the call? What are the implications of the earnings results for the company's long‑term growth and valuation? What is the market's reaction to the earnings release so far, and how is the stock price moving post‑release? How does the company's financial performance compare to that of its main competitors in the biotech/pharmaceutical sector? Did management address any macro‑economic or regulatory factors that could affect future performance? Are there any updates on the company's pipeline, especially concerning any late-stage clinical trials or FDA submissions? How does the reported revenue and profitability trend compare to the same quarter last year? Did Zealand Pharma provide any guidance or outlook for the upcoming quarters or fiscal year? What were the key financial metrics reported for Q2 2025, and how do they compare to analysts' expectations?